Comparative Efficacy of Esketamine Nasal Spray Versus Quetiapine Extended Release as Adjunctive Treatments for Treatment-Resistant Depression: A Systematic Review
Annals of Clinical Psychiatry July 29, 2026 Neha Ather, Mashal Zahid, Mohammad Hassan et al.
Background Depression remains a leading cause of disability and suicide worldwide, with treatment-resistant depression (TRD) affecting nearly 30% of individuals diagnosed with major depressive disorder. Esketamine nasal spray (NS) and quetiapine extended-release (XR) are both approved as adjunctive therapies for TRD; however, direct head-to-head comparisons are limited. Method A systematic...